| Popis: |
Backgrounds: Cellular and molecular changes can interact with genes and environmental factors to determine which cells age successfully and which go towards neurodegeneration. Trichostatin A (TSA) has been effectively investigated for cancer treatment, but it also has been shown to possess neurogenic potential. Also the potential pharmacological targeting of a set of powerful epigenetic mechanisms, novel DNA methyltransferase inhibitors RG108. Epigenetic drugs, which is currently been focused as an alternative approach for eliciting neuritogenic activity. Purpose: In this study, we aimed to combine the neurogenic effects of two epigenetic drugs on PC-12 Adh cell line, which are TSA and RG108 alone and in combination with neuronal growth factor (NGF). Methods: To investigate the cytotoxic effects of different TSA concentration (10, 50, 100, 400 nM and 1, 10, 100, 200, 400 ?M) alone and combined with RG108 (100 nM) on PC-12 Adh cells were evaluated by WST-1 assay at 24, 48, 72 hours. Also neuritogenic effects were investigated by neurite outgrowth analysis which was performed on digitized images of live cells taken under an inverted microscope. Results: As a result only 400 ?M TSA alone and combined with RG108 100 nM was slightly reduced cell viability of the PC-12 adh cells. We determined different non-cytotoxic group (RG108 (100 nM) and TSA (50 nM)) combination alone or in a combination with NGF (50 nM) acccording to WST-1 assay. According to the results, TSA(100nM)+RG108(50 nM)+NGF (50 nM) combination showed the highest neuritogenic effect on cells. Conclusions: In conclusion, TSA and RG108 combination therapy may be a potential agent for neurodegenerative diseases treatment with further investigations. |
